Souhaitez-vous accéder aux communiqués récents ?

Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed a statistically significant and clinically meaningful improvement in...

      TARA-002 demonstrates 72% complete response rate at any time, 67% complete response rate at the 6-month landmark and 55% complete response rate at the 12-month landmark in BCG-Naïve patients ...

SOLANA BEACH, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating...

Prenetics records Q1 2026 revenue of $36.0 million with IM8 revenue of $33.8 million, up 23.1% from IM8 revenue of $27.4 million in Q4 2025Raises full-year 2026 IM8 revenue guidance to $190 million to...

The Company intends to submit a Biologics License Application (BLA) for TARA-002 in Lymphatic Malformations (LMs) in 2H 2027 Hosting virtual investor webinar discussing LMs program with key opinion...

MARKHAM, Ontario, May 12, 2026 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) has filed a Business Acquisition Report on Form 51-102F4 (the “BAR”) on SEDAR+...

– Real world data showed clinically meaningful BMI reductions with setmelanotide in 62 adults with 12-month data living with acquired hypothalamic obesity (HO) in France – – Phase 3 analyses...

New York City, NY, May 08, 2026 (GLOBE NEWSWIRE) -- Let's start with something nobody in the snoring solutions industry wants to say out loud. Most anti-snoring products don't work. At least,...

Quarterly revenue of $1.378 billion and adjusted EBITDA of $166 million; GAAP income of $1.59/share and adjusted EPS of $2.10 DALLAS, May 07, 2026 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc....

– Quarterly results marked by 104% revenue growth and improved operating performance – – Company issues full-year 2026 revenue guidance – – Announces Humana is now covering the TULSA Procedure™ – ...